Onconostic Technologies/3N Diagnostics (OT/3NDx) is multi-sector healthcare platform company based on FOXC1, the master gene regulator driving metastasis in breast and other cancers. The company has developed 3 main business opportunities leading to sales revenues, strategic licensing, and potential exits:
DIAGNOSTIC: Early detection of aggressive metastatic cancer. First product Veresca®FOXC1 test has regulatory approval in EU and is in use in hospitals OUS.
THERAPEUTICS: Development of novel drugs preventing metastasis, complementary diagnostics for FDA-approved drugs via strategic licensing with Pharma.
DATA MANAGEMENT: Proprietary algorithms/databases for oncology management via strategic licensing with Big Data.
OT is based in the US. Its sister company 3NDx, is based in Northern Ireland to carry out manufacturing, marketing, regulatory (CE Mark), and accelerate worldwide product introduction.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 415 Howard Street, Suite 1501,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.3ndx.com
- HQ
- Evanston, Illinois
Onconostic Technologies/3n Diagnostic Group Questions
Onconostic Technologies/3N Diagnostic Group's website is http://www.3ndx.com
Onconostic Technologies/3N Diagnostic Group's LinkedIn profile is https://www.linkedin.com/company/onconostictechnologies3ndiagnosticsgroup
Onconostic Technologies/3N Diagnostic Group has
3 employees.
View email and phone details for 3
employees at Onconostic Technologies/3N Diagnostic Group.
Onconostic Technologies/3N Diagnostic Group's industry is
Biotechnology Research
Onconostic Technologies/3N Diagnostic Group's top competitors are
Imagen Technologies,
Genius Academy,
Cadrenal Therapeutics, Inc. (Nasdaq: Cvkd),
Fetalease,
3ndx 3n Diagnostics,
Altis Biosystems,
Adaptive Reader.
Onconostic Technologies/3N Diagnostic Group's categories are Biotechnology Research
Onconostic Technologies/3N Diagnostic Group's founding year is 2012
